Lineage Cell Valuation
| LCTX Stock | USD 0.61 0 0.23% |
Lineage Cell is undervalued. Lineage Cell Therapeutics secures a last-minute Real Value of $1.82 per share. The latest price of the firm is $0.6114. Our model forecasts the value of Lineage Cell Therapeutics from analyzing the firm fundamentals such as Operating Margin of (4.17) %, shares outstanding of 220.42 M, and Return On Equity of -0.35 as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Lineage Cell's valuation include:
Price Book 1.9958 | Enterprise Value 102.1 M | Enterprise Value Ebitda (8.84) | Price Sales 21.6425 | Enterprise Value Revenue 11.714 |
Undervalued
Today
Please note that Lineage Cell's price fluctuation is dangerous at this time. Calculation of the real value of Lineage Cell Therapeutics is based on 3 months time horizon. Increasing Lineage Cell's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Lineage Cell is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Lineage Stock. However, Lineage Cell's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.61 | Real 1.82 | Target 5.5 | Hype 0.59 | Naive 0.71 |
The intrinsic value of Lineage Cell's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Lineage Cell's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Lineage Cell Therapeutics helps investors to forecast how Lineage stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Lineage Cell more accurately as focusing exclusively on Lineage Cell's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Lineage Cell's intrinsic value based on its ongoing forecasts of Lineage Cell's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Lineage Cell's closest peers.
Lineage Cell Cash |
|
Lineage Valuation Trend
Analysing the historical paterns of Lineage Cell's enterprise value and its market capitalization is a good way to estimate and gauge the value of Lineage Cell Therapeutics over time and is usually enough for investors to make rational market timing decisions.
Lineage Cell Total Value Analysis
Lineage Cell Therapeutics is now anticipated to have valuation of 102.13 M with market capitalization of 133.88 M, debt of 2.95 M, and cash on hands of 66.36 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Lineage Cell fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
102.13 M | 133.88 M | 2.95 M | 66.36 M |
Lineage Cell Investor Information
About 51.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 2.0. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Lineage Cell Therapeutics recorded a loss per share of 0.1. The entity had not issued any dividends in recent years. The firm had 3:1 split on the 31st of October 1997. Lineage Cell Therapeutics is not in a good financial situation at this time. It has a very high odds of going through financial crisis in January.Lineage Cell Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Lineage Cell has an asset utilization ratio of 8.85 percent. This suggests that the Company is making $0.0885 for each dollar of assets. An increasing asset utilization means that Lineage Cell Therapeutics is more efficient with each dollar of assets it utilizes for everyday operations.Lineage Cell Ownership Allocation
Lineage Cell Therapeutics maintains a total of 220.42 Million outstanding shares. Over half of Lineage Cell's outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that shop for positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.Lineage Cell Profitability Analysis
The company reported the previous year's revenue of 8.95 M. Net Loss for the year was (21.49 M) with profit before overhead, payroll, taxes, and interest of 13.97 M.About Lineage Cell Valuation
Our relative valuation model uses a comparative analysis of Lineage Cell. We calculate exposure to Lineage Cell's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Lineage Cell's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 8.3 M | 8.7 M | |
| Pretax Profit Margin | (2.60) | (2.73) | |
| Operating Profit Margin | (2.77) | (2.90) | |
| Net Loss | (2.40) | (2.52) | |
| Gross Profit Margin | 0.92 | 0.97 |
Lineage Cell Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 172.7 M |
Lineage Cell Current Valuation Indicators
Valuation refers to the process of determining the present value of Lineage Cell Therapeutics and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Lineage we look at many different elements of the entity such as Lineage's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Lineage Cell, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Lineage Cell's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Lineage Cell's worth.Additional Tools for Lineage Stock Analysis
When running Lineage Cell's price analysis, check to measure Lineage Cell's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lineage Cell is operating at the current time. Most of Lineage Cell's value examination focuses on studying past and present price action to predict the probability of Lineage Cell's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lineage Cell's price. Additionally, you may evaluate how the addition of Lineage Cell to your portfolios can decrease your overall portfolio volatility.